European Biotech Stocks 2010/II
The EuroBiotech Stocks list offers a comparative tool for the performance of all listed European Biotech Stocks. To ease compatibility all quotes are converted to Euros. The performance is calculated over a period of 60 days before the effective date. Displayed highs and lows are taken from the last 52 weeks.
| Rank | Company | Perfor. | Quote | H/L |
| 1 | TopoTarget (DK) | 78% | 0.66 | 0.73/0.3 |
| 2 | GeneArt (D) | 39% | 9.58 | 9.7/3.4 |
| 3 | Epigenomics (D) | 25.4% | 2.66 | 4/1.5 |
| 4 | Basilea (CH) | 19.2% | 52.78 | 76.2/32.9 |
| 5 | Galapagos (B) | 16.5% | 11.41 | 11.5/5.2 |
| 6 | Vita 34 (D) | 15.9% | 5.09 | 6.3/2.1 |
| 7 | Advanced Med. Sol. (UK) | 14% | 0.42 | 0.46/0.25 |
| 8 | GW Pharmaceut. (UK) | 13.8% | 1.13 | 1.17/0.41 |
| 9 | FuturaGene (UK) | 12.1% | 0.89 | 0.97/0.34 |
| 10 | Algeta (N) | 11.1% | 7.15 | 9.9/1.3 |
| 11 | Biotec Pharmacon (N) | 10.4% | 0.59 | 5.07/0.39 |
| 12 | Evotec (D) | 9.3% | 1.98 | 2.45/0.57 |
| 13 | Sartorius VZ (D) | 9% | 17.78 | 18.5/6 |
| 14 | Plethora (UK) | 8.9% | 0.16 | 0.4/0.1 |
| 15 | Biocompatibles (UK) | 8.6% | 2.75 | 2.9/1 |
| 16 | Biolin (S) | 7.8% | 1.01 | 1.06/0.47 |
| 17 | Lonza (CH) | 7.3% | 56.88 | 80/47.2 |
| 18 | Syngenta (CH) | 7.1% | 192.45 | 194.7/136.5 |
| 19 | Phytopharm (UK) | 6.9% | 0.12 | 0.4/0.04 |
| 20 | Abcam (UK) | 5.6% | 11.83 | 0/5.5 |
| 21 | Photocure (N) | 5.4% | 5.3 | 6.4/2.9 |
| 22 | Thrombogenics (B) | 5.2% | 15.94 | 18.1/8.3 |
| 23 | Almirall (E) | 4.8% | 9.96 | 10.2/5.9 |
| 24 | Crucell (NL) | 4.3% | 14.5 | 17.6/12.5 |
| 25 | Virbac (F) | 4% | 73.75 | 78/50 |
| 26 | Qiagen (D) | 3.8% | 16.51 | 16.7/11.1 |
| 27 | MediGene (D) | 3.2% | 3.83 | 5.5/3.2 |
| 28 | Transgene (F) | 2.8% | 21.8 | 23.2/12.4 |
| 29 | Pronova (N) | 2.8% | 2.18 | 2.6/1.6 |
| 30 | Novozymes (DK) | 2.4% | 75.51 | 77.3/50.4 |
| 31 | Antisoma (UK) | 1.5% | 0.36 | 0.43/0.25 |
| 32 | BB Biotech (CH) | 1.3% | 50.09 | 52.2/37.8 |
| 33 | HBM Bioventures (CH) | 1.1% | 33.44 | 34/11.9 |
| 34 | Devgen (B) | .8% | 10.27 | 12.6/3.2 |
| 35 | Clavis Pharma (N) | .8% | 5.53 | 7.27/0.99 |
| 36 | Roche GS (CH) | .8% | 124.96 | 128.5/84.1 |
| 37 | Biotest VZ (D) | .7% | 36.28 | 45.2/24.6 |
| 38 | Alizyme (UK) | 0% | 0.01 | 0.17/0.02 |
| 39 | Cobra Bio (UK) | 0% | 0.02 | 0.07/0.01 |
| 40 | Affitech (DK) | 0% | 0.08 | 0.19/0.04 |
| 41 | Tepnel (UK) | 0% | 0.29 | 0.3/0.29 |
| 42 | Biotie (FIN) | 0% | 0.36 | 0.64/0.27 |
| 43 | MolMed (I) | 0% | 1.89 | 2/0.75 |
| 44 | Elan (IRL) | 0% | 5.41 | 6.8/2.2 |
| 45 | Agennix AG (D) | 0% | 5.5 | 7.23/0.86 |
| 46 | Genfit (F) | 0% | 7.08 | 8.3/5.1 |
| 47 | Jerini (D) | 0% | 7.79 | 8.3/7 |
| 48 | Bavarian Nordic (DK) | 0% | 40 | 40/21.5 |
| 49 | Speedel (CH) | 0% | 85.49 | 88.7/84.8 |
| 50 | UCB (B) | -1.3% | 32.4 | 33.8/19.1 |
| 51 | Proximagen (UK) | -1.3% | 1.18 | 1.6/1.1 |
| 52 | Paion (D) | -1.4% | 2.79 | 3.35/0.75 |
| 53 | Mologen (D) | -1.8% | 8.8 | 9.2/5.8 |
| 54 | Santhera (CH) | -1.9% | 16.88 | 34.7/13.4 |
| 55 | Fornix Bioscience (NL) | -2.2% | 8 | 8.9/5.9 |
| 56 | Sygnis Pharma (D) | -2.5% | 1.13 | 1.48/0.99 |
| 57 | Wilex (D) | -2.6% | 3.68 | 6.2/2.2 |
| 58 | Renovo (UK) | -3.4% | 0.3 | 0.39/0.25 |
| 59 | Octoplus (NL) | -3.5% | 1.35 | 1.89/0.86 |
| 60 | Active Biotech (S) | -3.8% | 9.88 | 13.2/3.5 |
| 61 | BioAlliance (F) | -3.8% | 4.75 | 6.1/2.2 |
| 62 | Axis-Shield (UK) | -3.9% | 4.32 | 5/3.1 |
| 63 | 4SC (D) | -4.1% | 3 | 3.6/2.6 |
| 64 | Ablynx (B) | -4.1% | 7.78 | 8.5/4.2 |
| 65 | Oxford Biomedica (UK) | -4.3% | 0.12 | 0.24/0.06 |
| 66 | Pharming (NL) | -4.3% | 0.44 | 0.88/0.34 |
| 67 | Newron (I) | -4.5% | 12.48 | 18.5/9.6 |
| 68 | Ark Therapeutics (UK) | -5% | 0.15 | 0.7/0.14 |
| 69 | Analytik Jena (D) | -5.2% | 8.52 | 9.9/5.7 |
| 70 | Vectura (UK) | -5.7% | 0.72 | 1.12/0.57 |
| 71 | Oncomethylome (B) | -6% | 3.58 | 7.4/3.1 |
| 72 | Addex Pharma (CH) | -6.2% | 7.94 | 27.8/6.7 |
| 73 | Cosmo (I) | -6.3% | 13.24 | 16.1/7.3 |
| 74 | Genoway (F) | -6.4% | 2.77 | 3.5/1.1 |
| 75 | MorphoSys (D) | -6.5% | 15.94 | 19/11.7 |
| 76 | DSM (NL) | -6.9% | 31.37 | 35.3/16.9 |
| 77 | BioXell (I) | -6.9% | 4.66 | 5.2/1.7 |
| 78 | ProStrakan (UK) | -7.2% | 1.13 | 1.71/0.58 |
| 79 | Tripep (S) | -7.2% | 0.08 | 0.22/0.04 |
| 80 | Fulcrum Pharma (UK) | -7.6% | 0.03 | 0.05/0.02 |
| 81 | Biofrontera (D) | -7.8% | 2.95 | 3.44/0.85 |
| 82 | Ipsen (F) | -8.3% | 36.85 | 42.2/24.1 |
| 83 | Genmab (DK) | -8.3% | 12.39 | 33.1/9.6 |
| 84 | Tigenix (F) | -8.4% | 3.56 | 5.5/2.7 |
| 85 | Henderson Morley (UK) | -8.8% | 00 | 0.01/0 |
| 86 | Nicox (F) | -8.9% | 5.29 | 10.9/4.8 |
| 87 | Vernalis (UK) | -9.6% | 0.82 | 1.23/0.03 |
| 88 | Metabolic Explorer (F) | -10.8% | 5.98 | 8/4.2 |
| 89 | Orexo (S) | -11% | 3.3 | 4.9/3.2 |
| 90 | Vivalis (F) | -11.5% | 9.38 | 11.2/4.5 |
| 91 | Sareum (UK) | -11.6% | 00 | 0.01/0 |
| 92 | Diagenic (N) | -12.2% | 0.31 | 0.61/0.26 |
| 93 | Zeltia (E) | -12.2% | 4 | 5.7/2.3 |
| 94 | ExonHit (F) | -12.3% | 3.2 | 7/2.2 |
| 95 | Cellectis (F) | -13% | 8.96 | 14.4/5.1 |
| 96 | Actelion (CH) | -14.2% | 31.56 | 43.8/29.4 |
| 97 | Eurofins Scientific (F) | -14.4% | 32.57 | 44.8/26.8 |
| 98 | Evolva (CH) | -14.8% | 1.86 | 4.97/0.33 |
| 99 | ReGen Therapeutics (UK) | -16.4% | 0.02 | 0.07/0.01 |
| 100 | Intercell (A) | -17% | 20.6 | 29.3/19.3 |
| 101 | Cytos (CH) | -17.9% | 7.54 | 17.2/6.7 |
| 102 | Silence Therapeutics (UK) | -20% | 0.14 | 0.36/0.14 |
| 103 | Ipsogen (F) | -32.3% | 5.75 | 9.6/5.5 |
| 104 | Decode (IC) | -57.1% | 0.02 | 0.6/0.01 |
Performance for 60 days, Highs and lows in 52 weeks.